

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076831 A3

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/4985 (2006.01)
C07D 471/04 (2006.01) A61K 31/437 (2006.01)
C07D 471/20 (2006.01) A61K 31/519 (2006.01)
C07D 491/20 (2006.01) A61K 31/52 (2006.01)
C07D 519/00 (2006.01) A61K 31/4725 (2006.01)
A61K 31/4375 (2006.01) A61K 31/444 (2006.01)
A61K 31/506 (2006.01) A61K 31/438 (2006.01)
A61K 31/53 (2006.01) A61K 31/5025 (2006.01)
A61K 31/5377 (2006.01) A61K 31/517 (2006.01)
A61K 31/5383 (2006.01)

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/054191

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/089,965 09 October 2020 (09.10.2020) US
63/151,468 19 February 2021 (19.02.2021) US

(71) Applicant: SCORPION THERAPEUTICS, INC.
[US/US]; One Winthrop Square, Suite 400, Boston, Mass-
achusetts 02110 (US).

(72) Inventors: GUZMAN-PEREZ, Angel; 20 Gilmore Road,
Belmont, Massachusetts 02478 (US). MILGRAM, Ben-
jamin C.; 44 Hubbard Road, Weston, Massachusetts 02493
(US). WHITE, Ryan D.; 34 Willow Ave., Somerville,
Massachusetts 02144 (US). ST. JEAN, JR., David; 25
Hunters Ln., Natick, Massachusetts 01760 (US).

(74) Agent: KENDALL, John T. et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))


(88) Date of publication of the international search report:

07 July 2022 (07.07.2022)



WO 2022/076831 A3

(54) Title: HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER



(57) Abstract: This disclosure provides chemical entities (e.g., a compound or a pharmaceutically accept-
able salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epider-
mal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2,
ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which
increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms
and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This dis-
closure also provides compositions containing the same as well as methods of using and making the same.